{"id":1019121,"date":"2026-11-09T18:23:24","date_gmt":"2026-11-09T23:23:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-participate-in-investor-conferences-in-november\/"},"modified":"2026-11-09T18:23:24","modified_gmt":"2026-11-09T23:23:24","slug":"nanobiotix-to-participate-in-investor-conferences-in-november","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-participate-in-investor-conferences-in-november\/","title":{"rendered":"Nanobiotix to Participate in Investor Conferences in November"},"content":{"rendered":"
\n

PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX<\/u><\/a> (Euronext: NANO – NASDAQ: NBTX – the \u201cCompany\u201d), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November:<\/p>\n

\n Jefferies Global Healthcare Conference in London<\/strong>
\n
Date: Monday, November 16, 2026
Presentation Time: 8:30am ET \/ 1:30pm GMT
Location: London (UK)
Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer<\/p>\n

\n UBS Global Biopharma Conference<\/strong>
\n
Date: Tuesday, November 17, 2026
Location: London (UK)<\/p>\n

\n About NANOBIOTIX<\/strong>\n <\/p>\n

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.<\/p>\n

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.<\/strong><\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/u><\/td>\n		\n
\n
Investor Relations Department<\/strong>
\n
\n Joanne Choi<\/em>
\n
\n VP, Investor Relations (US)<\/em>
\n
joanne.choi@nanobiotix.com<\/p>\n

Ricky Bhajun<\/em>
Director, Investor Relations (EU)<\/em>
+33 (0) 79 97 29 99
investors@nanobiotix.com<\/p>\n

<\/u><\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
France \u2013 HARDY<\/strong>
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr<\/a><\/td>\n		\n
Global \u2013 uncapped<\/strong>
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com<\/td>\n		\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Attachment<\/strong>\n <\/p>\n